Vanguard Group’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-769,761
Closed -$91.1M 4502
2021
Q1
$91.1M Buy
769,761
+22,696
+3% +$2.68M ﹤0.01% 2000
2020
Q4
$88.2M Sell
747,065
-94,252
-11% -$10.9M ﹤0.01% 1895
2020
Q3
$93.5M Sell
841,317
-69,091
-8% -$7.42M ﹤0.01% 1717
2020
Q2
$93M Sell
910,408
-82,235
-8% -$8.8M ﹤0.01% 1718
2020
Q1
$107M Buy
992,643
+48,052
+5% +$5.52M ﹤0.01% 1489
2019
Q4
$110M Buy
944,591
+43,921
+5% +$5.09M ﹤0.01% 1700
2019
Q3
$103M Sell
900,670
-49,751
-5% -$4.95M ﹤0.01% 1709
2019
Q2
$90.6M Buy
950,421
+29,178
+3% +$2.75M ﹤0.01% 1803
2019
Q1
$84.1M Buy
921,243
+21,651
+2% +$1.77M ﹤0.01% 1836
2018
Q4
$68.3M Buy
899,592
+26,040
+3% +$1.92M ﹤0.01% 1871
2018
Q3
$69.9M Buy
873,552
+90,532
+12% +$8.44M ﹤0.01% 1981
2018
Q2
$77.8M Buy
783,020
+70,776
+10% +$6.12M ﹤0.01% 1895
2018
Q1
$57.7M Buy
712,244
+12,616
+2% +$1.02M ﹤0.01% 2000
2017
Q4
$55.1M Buy
699,628
+162,995
+30% +$13.6M ﹤0.01% 2013
2017
Q3
$49.5M Buy
536,633
+512,947
+2,166% +$49.3M ﹤0.01% 2048
2017
Q2
$2.68M Buy
23,686
+19,169
+424% +$2.14M ﹤0.01% 3293
2017
Q1
$452K Hold
4,517
﹤0.01% 3776
2016
Q4
$486K Buy
4,517
+17
+0.4% +$1.99K ﹤0.01% 3741
2016
Q3
$560K Hold
4,500
﹤0.01% 3738
2016
Q2
$478K Hold
4,500
﹤0.01% 3806
2016
Q1
$515K Buy
4,500
+1,000
+29% +$117K ﹤0.01% 3785
2015
Q4
$499K Hold
3,500
﹤0.01% 3833
2015
Q3
$314K Buy
+3,500
New +$369K ﹤0.01% 3958

Vanguard Group's CBPO Position: Q2 2021 in Review

Vanguard Group sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2021, closing a stake of 769,761 shares — an estimated $91.1M sold.

Vanguard Group first reported a position in CBPO in Q3 2015 and held it in 23 quarters. The position peaked at $110M in Q4 2019. 0 funds tracked by Wall St. Rank hold CBPO as of Q2 2021.

  • Vanguard Group reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2021 after selling out during the quarter.
  • Vanguard Group sold 769,761 China Biologic Products Holdings, Inc. shares in Q2 2021, an estimated $91.1M.
  • Vanguard Group first reported a position in China Biologic Products Holdings, Inc. in Q3 2015 and held it in 23 quarters.
  • Vanguard Group's China Biologic Products Holdings, Inc. position peaked at $110M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2021.

Based on Vanguard Group's 13F filing for Q2 2021, filed 13 Aug 2021.